Table 1.
CAR T-cell-based therapies approved to treat hematologic cancers.
| Generic name | Brand name | Target antigen | Hematologic disease | Population | FDA approval trial (references) | ICANS rate (grade 3–4) |
|---|---|---|---|---|---|---|
| Tisagenlecleucel (tisa-cel) | Kymriah | CD19 | R/R B-ALL | Children and young | NCT02435849 ELIANA trial (4) | 40% (13%) |
| R/R B-NHL | Adult | NCT02445248 JULIET trial (5) | 21% (12%) | |||
| R/R Follicular Lymphoma | Adult | NCT03568461 ELARA trial (6) | 37.1% (>3.3%) | |||
| Axicabtagene ciloleucel (axi-cel) | Yescarta | CD19 | R/R B-NHL | Adult | NCT02348216 ZUMA-1 trial (7) | 64% (28%) |
| R/R Follicular Lymphoma | Adult | NCT03105336 ZUMA-5 trial (8) | 59% (19%) | |||
| Brexucabtagene autoleucel (brexu-cel) | Tecartus | CD19 | R/R B-ALL | Adult | NCT02614066 ZUMA 3 (9) | 60% (25%) |
| R/R MCL | Adult | NCT02601313 ZUMA 2 (10) | 63% (31%) | |||
| Lisocabtagene maraleucel (liso-cel) | Breyanzi | CD19 | R/R B-NHL | Adult | NCT02631044 TRANSCEND NHL 001 (11) | 30% (10%) |
| Idecabtagene vicleucel (ide-cel) | Abecma | BCMA | R/R MM | Adult | NCT03361748 KARMMA trial (11) | 18% (3%) |
| Ciltacabtagene autoleucel (cilta-cel) | Carvykti | BCMA | R/R MM | Adult | NCT03548207 CARTITUDE-1 (12) | 21% (9%) |
ICANS, immune effector cell-associated neurotoxicity syndrome; RR, relapsed/refractory; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma. *Per CTCAE v4.03.